Aditxt, Inc. - Common Stock (ADTX)

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating health innovations, announced it will implement a 1-for-27 reverse stock split of its common stock, effective at the opening of trading on the Nasdaq Capital Market on May 18, 2026. The reverse split is intended to bring the company into compliance with Nasdaq’s minimum bid price requirement, reducing outstanding common shares from approximately 13.8 million to about 510,123, with the stock continuing to trade under the symbol ADTX.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-27 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on May 18, 2026, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the annual meeting of stockholders held on May 1, 2026, with the final ratio determined by the Company’s board of directors.

Aditxt (NASDAQ: ADTX) announced its precision oncology subsidiary, Ignite Proteomics, was featured in a peer-reviewed study published in npj Precision Oncology, a Nature journal, evaluating treatment outcomes in metastatic breast cancer patients receiving trastuzumab deruxtecan. The study found that quantitative HER2-related assays, including Ignite’s Reverse Phase Protein Array platform, provided more predictive insight into patient outcomes than traditional immunohistochemistry methods in certain sub-cohorts, highlighting the potential of advanced biomarker approaches to improve treatment selection in oncology.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd, marketed as Enhertu® by AstraZeneca and Daiichi Sankyo) and assessed multiple quantitative HER2-related assays for their association with treatment outcomes.

Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, announced the appointment of Jeff Busch as chief executive officer of its subsidiary Ignite Proteomics, a commercial-stage precision oncology platform focused on guiding cancer therapy selection through functional protein profiling, with Busch expected to lead commercial expansion and evaluate strategic growth and financing opportunities as the company scales its platform designed to help physicians match patients with the most effective targeted therapies.

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”).

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced the acquisition of Ignite Proteomics LLC, a commercial-stage precision oncology company focused on improving therapy selection in cancer care through functional proteomics. Ignite’s Reverse Phase Protein Array platform is designed to measure protein expression and activity directly from tumor samples, providing insight into whether targeted therapies are likely to be effective, information that may not be captured by genomic testing alone. Under the terms of the transaction, Aditxt acquired Ignite through the issuance of 36,000 shares of newly designated Series A-2 Convertible Preferred Stock with an aggregate stated value of $36 million, with Ignite to operate as a subsidiary within Aditxt’s oncology initiatives.

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone.